Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Roswell Park Cancer Institute
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
University Health Network, Toronto
M.D. Anderson Cancer Center
University Health Network, Toronto
TCR2 Therapeutics
TCR2 Therapeutics
Roswell Park Cancer Institute
University Health Network, Toronto
ImmunoVaccine Technologies, Inc. (IMV Inc.)